665 related articles for article (PubMed ID: 28668871)
41. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes.
van Rijk MC; Peterse JL; Nieweg OE; Oldenburg HS; Rutgers EJ; Kroon BB
Cancer; 2006 Aug; 107(3):467-71. PubMed ID: 16804924
[TBL] [Abstract][Full Text] [Related]
42. Breast cancer metastasis burden in sentinel nodes analysed using one-step nucleic acid amplification predicts axillary nodal status.
Milner TD; de Lusignan S; Jones S; Jackson PA; Layer GT; Kissin MW; Irvine TE
Breast; 2015 Oct; 24(5):568-75. PubMed ID: 26032111
[TBL] [Abstract][Full Text] [Related]
43. [Validation study of the sentinel lymph node (SLN) method in invasive breast carcinoma. Personal data and review of the literature].
Langer I; Zuber M; Köchli OR; Kocher T; Müller-Brand J; Torhorst J; Harder F
Swiss Surg; 2000; 6(3):128-36. PubMed ID: 10894014
[TBL] [Abstract][Full Text] [Related]
44. Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
Imoto S; Yamauchi C; Komoike Y; Tsugawa K; Yotsumoto D; Wada N; Ueno T; Oba MS; Shien T; Sugae S; Tsuda H; Yoneyama K
Breast Cancer; 2017 May; 24(3):427-432. PubMed ID: 27553957
[TBL] [Abstract][Full Text] [Related]
45. Management and results of treatment of breast cancer patients having sentinel lymph node micrometastases.
Nowikiewicz T; Srutek E; Jankowski M; Las-Jankowska M; Klag M; Kozak D; Glowacka I; Zegarski W
Neoplasma; 2014; 61(3):299-304. PubMed ID: 24824931
[TBL] [Abstract][Full Text] [Related]
46. Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
Majid S; Rydén L; Manjer J
BMC Cancer; 2019 Jun; 19(1):626. PubMed ID: 31238899
[TBL] [Abstract][Full Text] [Related]
47. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
Fan YG; Tan YY; Wu CT; Treseler P; Lu Y; Chan CW; Hwang S; Ewing C; Esserman L; Morita E; Leong SP
Ann Surg Oncol; 2005 Sep; 12(9):705-11. PubMed ID: 16079953
[TBL] [Abstract][Full Text] [Related]
48. Factors predicting the non-sentinel lymph node involvement in breast cancer patients with sentinel lymph node metastases.
Boler DE; Uras C; Ince U; Cabioglu N
Breast; 2012 Aug; 21(4):518-23. PubMed ID: 22410110
[TBL] [Abstract][Full Text] [Related]
49. Micrometastatic disease and isolated tumor cells as a predictor for additional breast cancer axillary metastatic burden.
Cyr A; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3(0 3):303-11. PubMed ID: 20853051
[TBL] [Abstract][Full Text] [Related]
50. Does the presence of sentinel lymph node macrometastases in breast cancer patients require axillary lymph node dissection?-Single-center analysis.
Nowikiewicz T; Zegarski W; Pagacz K; Nowacki M; Morawiec-Sztandera A; Głowacka-Mrotek I; Sowa M; Biedka M; Kołacińska A
Breast J; 2018 Sep; 24(5):724-729. PubMed ID: 29476570
[TBL] [Abstract][Full Text] [Related]
51. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer.
Noguchi M
Eur J Surg Oncol; 2008 Feb; 34(2):129-34. PubMed ID: 17498911
[TBL] [Abstract][Full Text] [Related]
52. A differential intra-operative molecular biological test for the detection of sentinel lymph node metastases in breast carcinoma. An extended experience from the first U.K. centre routinely offering the service in clinical practice.
Babar M; Madani R; Thwaites L; Jackson PA; Devalia HL; Chakravorty A; Irvine TE; Layer GT; Kissin MW
Eur J Surg Oncol; 2014 Mar; 40(3):282-8. PubMed ID: 24331309
[TBL] [Abstract][Full Text] [Related]
53. Outcomes of breast cancer patients with micrometastases and isolated tumor cells in sentinel lymph nodes.
Gloyeske NC; Goreal W; O'Neil M; Connor C; Tawfik OW; Fan F
In Vivo; 2011; 25(6):997-1001. PubMed ID: 22021696
[TBL] [Abstract][Full Text] [Related]
54. Breast lymphoscintigraphy for sentinel node identification in breast cancers with clinically-negative axillary nodes.
Namwongprom S; Boonyaprapa S; Ekmahachai M; Vilasdechanon N; Somwangprasert A; Sumitsawan S; Taya P
Singapore Med J; 2005 Dec; 46(12):688-92. PubMed ID: 16308641
[TBL] [Abstract][Full Text] [Related]
55. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection.
Calhoun KE; Hansen NM; Turner RR; Giuliano AE
Am J Surg; 2005 Oct; 190(4):588-91. PubMed ID: 16164927
[TBL] [Abstract][Full Text] [Related]
56. A simple nomogram to evaluate the risk of nonsentinel node metastases in breast cancer patients with minimal sentinel node involvement.
Meretoja TJ; Strien L; Heikkilä PS; Leidenius MH
Ann Surg Oncol; 2012 Feb; 19(2):567-76. PubMed ID: 21792511
[TBL] [Abstract][Full Text] [Related]
57. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system.
Huang TW; Kuo KN; Chen KH; Chen C; Hou WH; Lee WH; Chao TY; Tsai JT; Su CM; Huang MT; Tam KW
Int J Surg; 2016 Oct; 34():73-80. PubMed ID: 27562691
[TBL] [Abstract][Full Text] [Related]
58. Validation of a technique using microbubbles and contrast enhanced ultrasound (CEUS) to biopsy sentinel lymph nodes (SLN) in pre-operative breast cancer patients with a normal grey-scale axillary ultrasound.
Cox K; Sever A; Jones S; Weeks J; Mills P; Devalia H; Fish D; Jones P
Eur J Surg Oncol; 2013 Jul; 39(7):760-5. PubMed ID: 23632319
[TBL] [Abstract][Full Text] [Related]
59. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
[TBL] [Abstract][Full Text] [Related]
60. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
